


AMENDMENTS TO THE CLAIMS

Please amend the claims to read as follows:

1. **(Currently Amended)** A method for the treatment or inhibition of hypercholesterolemia or hypertriglyceridemia in an affected patient, comprising the step of:
administering to the patient a composition comprising a therapeutically-effective amount
of a compound of either Formula I:


a) Formula I



wherein R and R₁ are independently selected from the group consisting of H, lower alkoxy (C₁₋₆), or lower alkyl (C₁₋₆); R₂ is selected from the group consisting of aryl (C₆₋₁₂) and substituted aryl; M is hydrogen, sodium, potassium, ammonium, diethanolamine, cyclohexylamine, a naturally-occurring amino acid of MW less than 500 kD, lower alkyl (C₁₋₆), cycloalkyl, or aryl (C₆₋₁₂); and n is 0-5; or

b) Formula III:


Formula III



wherein R and R₁ are independently selected from the group consisting of H, lower alkoxy (C₁₋₆), or lower alkyl (C₁₋₆); R₂ is selected from the group consisting of aryl (C₆₋₁₂) and substituted aryl; M is hydrogen, sodium, potassium, ammonium, diethanolamine, cyclohexylamine, a naturally-occurring amino acid of MW less than 500 kD, lower alkyl (C₁₋₆), cycloalkyl, or aryl (C₆₋₁₂); and n is 0-5; or

c) Formula IV:

Formula IV





~~wherein R and R₁ are independently selected from the group consisting of H, lower alkoxy (C₁₋₆), or lower alkyl (C₁₋₆); R₂ is selected from the group consisting of aryl (C₆₋₁₂) and substituted aryl; M is hydrogen, sodium, potassium, ammonium, diethanolamine, cyclohexylamine, a naturally-occurring amino acid of MW less than 500 kD, lower alkyl (C₁₋₆), cycloalkyl, or aryl (C₆₋₁₂); and n is 0-5; or,~~

d) any combination thereof.

2. (Original) The method of claim 1, wherein in said composition M is hydrogen, potassium or sodium; n is 0-2; R and R₁ are independently selected from the group consisting of H and C₃H₇; R₁ is selected from the group consisting of H, CH₃, CH₃-O-, C₂H₅, and C₃H₇; and R₂ is an aryl (C₆₋₁₂) or a substituted aryl selected from the group consisting of Formula II:

Formula II





, wherein X is a halogen, lower alkyl (C₁₋₆), lower alkoxy (C₁₋₆), cycloalkyl, cycloalkoxy, aryl (C₆₋₁₂), substituted aryl or hydroxy and n is 0, 1, 2, 3, or 4.

3. (Original) The method of claim 2, wherein said therapeutically-effective amount is from 20 mg/kg/day to 2500 mg/kg/day.

4. (Original) The method of claim 1, wherein said composition further comprises at least one pharmaceutically-acceptable carrier, diluent, or excipient.

5. to 7. (Cancelled)

8. (Original) The method of claim 2, wherein said composition further comprises at least one pharmaceutically-active carrier, diluent, or excipient.

9. to 15. (Cancelled)

16. **(Currently Amended)** The method of claim 2, wherein said composition comprises an effective amount of ~~[phenylbutyric acid,]~~ phenylbutylglutamine~~[,]~~ or isophenylbutylglutamine or pharmaceutically acceptable salts thereof.

17. and 18. (Cancelled)

19. **(Currently Amended)** The method of claim 1, wherein the compound of Formula I is the sodium salt of phenylacetylglutamine~~[,]~~ and the compound of Formula III is the sodium salt of phenylacetylisoglutamine~~[,]~~ ~~and the compound of Formula IV is the sodium salt of phenylacetate].~~

20. (Previously Added) The method of claim 1, wherein said therapeutically-effective amount is from 20 mg/kg/day to 2500 mg/kg/day.

21. (Cancelled)
